Ziska Pharmaceuticals Limited
Megestrol Acetate
Megestrol Verbal Suspension is demonstrated for the treatment of anorexia, cachexia, or an unexplained, critical weight misfortune in patients with a determination of Procured Immunodeficiency Disorder (Helps) & cancer.
Several researchers have reported on Megestrol Acetate's appetite-stimulating properties and its potential usage in anorexia and cachexia. Although the exact mechanism by which Megestrol Acetate causes effects in anorexia and cachexia is unknown at this time, some studies suggest that there is a statistically significant negative correlation between the levels of pro-inflammatory cytokines such as IL1 IL6 and TNF, as well as improvements in quality of life and weight gain, with various nutritional parameters.
Megestrol Acetate plasma concentrations are determined not only by the technique utilized, but also by the drug's intestinal and hepatic inactivation, which can be influenced by factors such as intestinal tract motility, intestinal bacteria, antibiotics used, body weight, food, and liver function. The effect of meals on Megestrol Acetate Oral Suspension bioavailability has not been studied. Urine is the primary route of medication excretion in humans. In healthy subjects, the mean elimination half life ranged from 20 to 50 hours.
The recommended adult initial dosage of Megestol Oral Suspension is 800 mg/day (20 ml/day).
When Megestrol Acetate is combined with Zidovudine or Rifabutin, pharmacokinetic investigations demonstrate that there are no substantial changes in pharmacokinetic parameters that would necessitate dosage adjustments. The pharmacokinetics of Megestrol Acetate were not examined with Zidovudine or Rifabutin.
History of hypersensitivity to Megestrol Acetate or any component of the formulation
Known or suspected pregnancy
Adverse events which occurred in at least 5% of patients in any arm of the two clinical efficacy trials and the open trial are listed below by treatment group. These adverse events should be considered by the physician when prescribing Megestrol Acetate. Those are- diarrhea, impotence, rash, flatulence, hypertension, asthenia, insomnia, nausea, anaemia, fever, libido decreased, dyspepsia, hyperglycemia, headache, vomiting, pneumonia & urinary frequency.
Adverse events which occurred in 1% to 3% of all patients enrolled in the two clinical efficacy trials with at least one follow-up visit during the first 12 weeks of the study are listed below by body system.
Pregnancy Category X. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.Because of the potential for adverse effects on the newborn, nursing should be discontinued if Megestrol Acetate is required.
General weight reduction therapy with Megestrol Acetate should be started only when treatable causes of weight loss have been identified and treated. Possible cancers, systemic infections, gastrointestinal issues affecting absorption, endocrine disease, and renal or mental ailments are among the treatable reasons. The effects of the drug on HIV viral replication are yet to be determined. In patients with a history of thromboembolic illness, use with caution. Diabetics' Use: The usage of Megestrol Acetate has been linked to an increase in insulin needs and an exacerbation of pre-existing diabetes.
Hormonal Chemotherapy
Temperatures should be kept between 20 and 25 degrees Celsius. Protect yourself from the heat. Before using, give it a good shake.
Ziska Pharmaceuticals Ltd.